173 related articles for article (PubMed ID: 24687830)
1. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Schaid DJ; Spraggs CF; McDonnell SK; Parham LR; Cox CJ; Ejlertsen B; Finkelstein DM; Rappold E; Curran J; Cardon LR; Goss PE
J Clin Oncol; 2014 Aug; 32(22):2296-303. PubMed ID: 24687830
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Spraggs CF; Parham LR; Briley LP; Warren L; Williams LS; Fraser DJ; Jiang Z; Aziz Z; Ahmed S; Demetriou G; Mehta A; Jackson N; Byrne J; Andersson M; Toi M; Harris L; Gralow J; Zujewski JA; Crescenzo R; Armour A; Perez E; Piccart M
Pharmacogenomics J; 2018 May; 18(3):480-486. PubMed ID: 28786423
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Parham LR; Briley LP; Li L; Shen J; Newcombe PJ; King KS; Slater AJ; Dilthey A; Iqbal Z; McVean G; Cox CJ; Nelson MR; Spraggs CF
Pharmacogenomics J; 2016 Apr; 16(2):180-5. PubMed ID: 25987243
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.
Spraggs CF; Parham LR; Hunt CM; Dollery CT
Clin Pharmacol Ther; 2012 Apr; 91(4):647-52. PubMed ID: 22357454
[TBL] [Abstract][Full Text] [Related]
5. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Spraggs CF; Budde LR; Briley LP; Bing N; Cox CJ; King KS; Whittaker JC; Mooser VE; Preston AJ; Stein SH; Cardon LR
J Clin Oncol; 2011 Feb; 29(6):667-73. PubMed ID: 21245432
[TBL] [Abstract][Full Text] [Related]
6. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Xu CF; Johnson T; Wang X; Carpenter C; Graves AP; Warren L; Xue Z; King KS; Fraser DJ; Stinnett S; Briley LP; Mitrica I; Spraggs CF; Nelson MR; Tada H; du Bois A; Powles T; Kaplowitz N; Pandite LN
Clin Cancer Res; 2016 Mar; 22(6):1371-7. PubMed ID: 26546620
[TBL] [Abstract][Full Text] [Related]
7. HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis.
Tangamornsuksan W; Kongkaew C; Scholfield CN; Subongkot S; Lohitnavy M
Pharmacogenomics J; 2020 Feb; 20(1):47-56. PubMed ID: 31383939
[TBL] [Abstract][Full Text] [Related]
8. Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.
Parham LR; Briley LP; King KS; Byrne J; Rappold E; Goss PE; Spraggs CF
Pharmacogenomics; 2015; 16(11):1227-9. PubMed ID: 26265235
[TBL] [Abstract][Full Text] [Related]
9. No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.
Faulkner L; Meng X; Naisbitt DJ; Spraggs CF; Park BK
Chem Res Toxicol; 2016 Dec; 29(12):2111-2113. PubMed ID: 27989141
[TBL] [Abstract][Full Text] [Related]
10. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury.
Donaldson PT; Daly AK; Henderson J; Graham J; Pirmohamed M; Bernal W; Day CP; Aithal GP
J Hepatol; 2010 Dec; 53(6):1049-53. PubMed ID: 20800921
[TBL] [Abstract][Full Text] [Related]
11. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
Boyle FM; Smith IE; O'Shaughnessy J; Ejlertsen B; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Amonkar M; Huang Y; Rappold E; Williams LS; Wang-Silvanto J; Kaneko T; Finkelstein DM; Goss PE;
Eur J Cancer; 2015 Apr; 51(6):685-96. PubMed ID: 25752740
[TBL] [Abstract][Full Text] [Related]
12. The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01.
Hirasawa M; Hagihara K; Okudaira N; Izumi T
PLoS One; 2015; 10(6):e0130928. PubMed ID: 26098642
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib-induced hepatitis: a case report.
Peroukides S; Makatsoris T; Koutras A; Tsamandas A; Onyenadum A; Labropoulou-Karatza C; Kalofonos H
World J Gastroenterol; 2011 May; 17(18):2349-52. PubMed ID: 21633602
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.
Petros Z; Makonnen E; Aklillu E
OMICS; 2017 Mar; 21(3):123-131. PubMed ID: 28253087
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
[TBL] [Abstract][Full Text] [Related]
17. Risk genes and autoantibodies in Egyptian children with type 1 diabetes - low frequency of autoantibodies in carriers of the HLA-DRB1*04:05-DQA1*03-DQB1*02 risk haplotype.
El-Amir MI; El-Feky MA; Laine AP; Härkönen T; El-Badawy O; Eltayeb AA; El-Melegy TT; Kiviniemi M; Knip M; Ilonen J
Diabetes Metab Res Rev; 2015 Mar; 31(3):287-94. PubMed ID: 25256132
[TBL] [Abstract][Full Text] [Related]
18. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease.
Andrade RJ; Lucena MI; Alonso A; García-Cortes M; García-Ruiz E; Benitez R; Fernández MC; Pelaez G; Romero M; Corpas R; Durán JA; Jiménez M; Rodrigo L; Nogueras F; Martín-Vivaldi R; Navarro JM; Salmerón J; de la Cuesta FS; Hidalgo R
Hepatology; 2004 Jun; 39(6):1603-12. PubMed ID: 15185301
[TBL] [Abstract][Full Text] [Related]
19. HLA-C alleles confer risk for anti-citrullinated peptide antibody-positive rheumatoid arthritis independent of HLA-DRB1 alleles.
Nordang GB; Flåm ST; Maehlen MT; Kvien TK; Viken MK; Lie BA
Rheumatology (Oxford); 2013 Nov; 52(11):1973-82. PubMed ID: 23901134
[TBL] [Abstract][Full Text] [Related]
20. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
